Publication | Closed Access
Landiolol, an ultra-short-acting β?-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study).
32
Citations
0
References
2012
Year
Cardiovascular DiseaseMedicineCardiovascular PharmacologyUltra-short-acting βJl-knight StudyPharmacotherapyAnesthesiologyAtrial FibrillationPublic HealthPharmacologyCardiologyCardiothoracic SurgeryCardiovascular Translational Research
No additional data available for this publication yet. Check back later!